Target intelligence / Profile preview

Mucin disulfide networks

Molecular classification
Glycoprotein, Protein polymer, Extracellular matrix component
01

Overview

Mucin disulfide networks are the primary structural components of the airway mucus gel, consisting of large, gel-forming glycoproteins, specifically MUC5AC and MUC5B (Bonser et al., 2016, JCI Insight). These mucins form high-molecular-weight polymers through intermolecular disulfide bonds between their cysteine-rich domains, which are essential for the viscoelastic properties of mucus (Fahy & Dickey, 2010, NEJM). In healthy individuals, these networks facilitate mucociliary clearance and provide a protective barrier against pathogens; however, in chronic inflammatory airway diseases like cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD), the networks become excessively cross-linked and dehydrated (Yuan et al., 2015, JCI). This leads to the formation of thick, stagnant mucus plugs that obstruct airflow and promote infection. Therapeutic agents known as mucolytics, such as N-acetylcysteine (NAC), target these networks by acting as reducing agents that cleave the disulfide bonds (DrugBank DB06151). This chemical reduction breaks the mucin polymers into smaller subunits, significantly decreasing mucus viscosity and improving the patient's ability to clear secretions via coughing or ciliary action. Beyond mucins, other disulfide-containing proteins like albumin can also be incorporated into these pathological networks, further increasing their tenacity.

Other names
Airway mucus gelMucin polymersGel-forming mucinsMUC5AC-MUC5B complexMucin disulfide-containing proteinsMucin disulfide networks and other disulfide-containing proteins in airway secretions
02

Mechanism of action

Reduction of intermolecular disulfide bonds to depolymerize mucin networks and decrease mucus viscosity.

03

Biological functions

Mucociliary clearanceInnate immunityPhysical barrierHydration
04

Disease associations

Cystic fibrosisChronic obstructive pulmonary diseaseAsthmaBronchiectasis
05

Safety considerations

BronchospasmAirway irritationDisruption of protective barrier
06

Interacting drugs

N-acetylcysteine

3 more in the full profile.

07

Biomarkers

Sputum viscosityForced expiratory volume in 1 second (FEV1)Mucus solids contentMucus hydration levels

Beyond the preview

Go deeper on Mucin disulfide networks.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mucin disulfide networks.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call